

# ENDING PAEDIATRIC AIDS



Paediatric HIV remains a global issue

**1.8 MILLION**

children are living with HIV around the world<sup>1</sup>



**89%**

of new HIV infections in children are in sub-Saharan Africa<sup>1</sup>



The majority of AIDS-related deaths still occur during the first five years of life<sup>2</sup>

In the past decade, there have been significant advancements made towards the UN goal of ending paediatric AIDS by 2030:<sup>3</sup>

- the rate of new HIV infections in children has declined by 52% since 2010<sup>1</sup>
- 53% of children living with HIV have access to treatment<sup>1</sup>
- 85% of pregnant women living with HIV had access to ARTs to prevent transmission of HIV to their child in 2019.<sup>1</sup>



However, there is still progress to be made:



**Paediatric HIV treatment**

There is a limited availability of optimised paediatric formulations of antiretrovirals<sup>2</sup>




**Mother-to-child transmission of HIV**

Without intervention, transmission rates range from 15% to 45%<sup>4</sup>



Half of these MTCTs occur during breastfeeding due to insufficient testing of HIV positive mothers<sup>2</sup>



## LEAVING NO CHILD LIVING WITH HIV BEHIND



As the only company 100% focused on HIV, we are committed to addressing the gaps in paediatric HIV treatment and management of care.

We recognise that if we are to reach the UN goal of ending paediatric AIDS by 2030, this needs to be a global effort.

To find out more about paediatric HIV care, please visit: <https://viihealthcare.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/>

## AT ViiV HEALTHCARE, WE CONTINUE TO:



**Support community initiatives** focused on ending paediatric AIDS and mother-to-child transmission of HIV through our **Positive Action** programmes



**Drive science and innovation** in developing age-appropriate formulations<sup>5</sup>



**Accelerate access** to age-appropriate formulations across the globe so that children living with HIV have access to optimal treatment<sup>6</sup>

By collaborating with the global HIV community, we hope to maintain momentum towards our collective goal and get closer to ending paediatric AIDS.

REFERENCES

1. UNAIDS. Global HIV & AIDS Statistics – 2020 Fact Sheet. Available at: <https://www.unaids.org/en/resources/fact-sheet> Last accessed March 2021.  
 2. UNAIDS. Get on the fast-track. The life-cycle approach to HIV. Available at: [https://www.unaids.org/sites/default/files/media\\_asset/Get-on-the-Fast-Track\\_en.pdf](https://www.unaids.org/sites/default/files/media_asset/Get-on-the-Fast-Track_en.pdf) Last accessed March 2021.  
 3. UNAIDS. Fast Track – Ending the AIDS epidemic by 2030. Available at: [https://www.unaids.org/en/resources/documents/2014/JC2686\\_WAD2014report](https://www.unaids.org/en/resources/documents/2014/JC2686_WAD2014report) Last accessed March 2021.  
 4. World Health Organization. HIV/AIDS. Mother-to-child transmission of HIV. Available at: <https://www.who.int/hiv/topics/mtct/about/en/#:~:text=The%20transmission%20of%20HIV%20from,from%2015%25%20to%2045%25>. Last accessed March 2021.  
 5. ViiV Healthcare. US FDA approval of the first-ever dispersible tablet formulation of dolutegravir. June 2020. Available at: <https://viihealthcare.com/en-gb/media/press-releases/2020/june/vii-healthcare-announces-us-fda-approval-of-the-first-ever-disp/> Last accessed March 2021.  
 6. ViiV Healthcare. Innovative Public-Private Partnership Initiative to improve the lives of CLHIV. Available at: <https://viihealthcare.com/en-gb/media/press-releases/2018/july/innovative-public-private-partnership-initiative-to-accelerate-development-of-optimal-paediatric-formulations-of-dolutegravir-to-improve-the-lives-of-clhiv/> Last accessed March 2021.